Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
Psychopharmacology · 2025
DOI: 10.1007/s00213-024-06733-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology, 2025. Verfasst von Mona Irrmischer und 4 weiteren Autor:innen. Beteiligte Einrichtung: GGZ Research, Hersencentrum Mental Health Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Psilocybin, Personality, Hallucinogens, Affect. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rationale
Psychedelic-assisted therapy is increasingly applied within mental health treatment.
Objectives
This study focused on factors moderating changes in the acute and long-term effects of an individual psilocybin-assisted program on depression, anxiety, PTSD and personality structures by including demographic factors, subjective experience and degree of mystical type experiences during the dosing, as well as emotional breakthrough and personal growth after the program.
Methods
At baseline, 1 week and 3 months after the psilocybin program participants completed the Generalized Anxiety Disorder Assessment (GAD-7), Patient Health Questionnaire (PHQ-9), PTSD Checklist for DSM-5 (PCL-5) and NEO Five-Factor Inventory-3 (NEO-FFI-3). In addition, after the dosing the Mystical Experiences Questionnaire (MEQ-30), Posttraumatic Growth Inventory (PTGI) and Emotional Breakthrough Inventory (EBI) were administered. Moderation effects were established using linear mixed-model analysis.
Results
A single high dose of psilocybin in combination with therapy was found to lower symptoms of anxiety, depression, PTSD and neuroticism over a period of 3-months. Scores on openness and conscientiousness increased after the treatment only. Participants reported mystical type experiences, emotional breakthrough and personal growth. These subjective experiences together with demographic factors were moderating the observed positive changes.
Conclusions
Findings indicate that individual psilocybin-assisted therapy has the potential for beneficial effects on mood and personality characteristics. Moreover, the study highlights the importance of subjective experiences and demographic factors in moderating this effect. This study adds to the ongoing research on psilocybin-assisted therapy by investigating contributing factors for optimizing this evolving type of therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GGZ Research, Hersencentrum Mental Health Institute, Amsterdam, The Netherlands.
- PsyInternational Therapy, Utrecht, The Netherlands.
- Novacare Solutions, Nijmegen, The Netherlands.
- GGZ Research, Hersencentrum Mental Health Institute, Amsterdam, The Netherlands. j.b.deijen@vu.nl.
- Faculty of Behavioural and Movement Sciences, Department of Clinical, Neuro- and Developmental Psychology, Section Clinical Neuropsychology, Vrije Universiteit, Amsterdam, The Netherlands. j.b.deijen@vu.nl.
- GGZ Research, Academic Center for Trauma and Personality, Amsterdam, Netherlands.
Zitieren
APA
Irrmischer, M., Puxty, D., Yıldırım, B. O., Deijen, J. B., & Engelbregt, H. (2025). Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. Psychopharmacology. https://doi.org/10.1007/s00213-024-06733-3
Vancouver
Irrmischer M, Puxty D, Yıldırım BO, Deijen JB, Engelbregt H. Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. Psychopharmacology. 2025. doi:10.1007/s00213-024-06733-3
BibTeX
@article{Irrmischer2025,
author = {Irrmischer, Mona and Puxty, Drew and Yıldırım, Barış Onur and Deijen, Jan Berend and Engelbregt, Hessel},
title = {Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation},
journal = {Psychopharmacology},
year = {2025},
doi = {10.1007/s00213-024-06733-3}
}
EUVIMED